Paris, France and Cambridge, Massachusetts, USA, February 7, 2017 – NANOBIOTIX , a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today the appointment of Alain Dostie, a senior executive from the pharmaceutical industry, as its Chief Operating Officer . Mr. Dostie will lead Nanobiotix’s operations, including development, manufacturing, market access and sales, for the Company’s lead product NBTXR3, which could obtain a CE Mark approval in 2017.